Publix Pharmacy adds Montelukast to its Free Medication Program
LAKELAND, Fla. — Publix Pharmacy added Montelukast — a prescription medication for asthma and allergies — to its Free Medication Program.
The Publix program provides up to a 90-day supply of certain common prescription medications at no charge to pharmacy customers for as a long as prescribed.
“We’re always happy to help our customers get the medications they need to treat chronic conditions,” said VP of Pharmacy Operations Fred Ottolino. “Montelukast is an excellent addition to the list of generic prescription medications currently in our Free Medication Program, and it’s the first one we’ve added for the treatment of asthma.”
Montelukast is used for long-term treatment of asthma in adults and children, and it is sometimes used to treat symptoms of indoor and outdoor allergies. It works by blocking a substance called leukotriene, which can trigger inflammation and allergy symptoms. Publix is offering it in 4 mg and 5mg chewable tablets for children and 10 mg oral tablets for adults as part of its free program.
Other medications in the Publix Free Medication Program include amlodipine, lisinopril, metformin and five common antibiotics — amoxicillin, ampicillin, sulfamethoxazole/trimethroprim (SMZ-TMP) and penicillin VK.
Health care leaders gather in Washington
WASHINGTON — Leaders across the health care continuum on Thursday gathered in Washington, D.C. to offer perspectives on efforts currently underway to move the healthcare system toward one that rewards innovation, delivers better quality and puts the patient at the center of the value equation. The meeting was convened by The Value Collaborative, an initiative of America’s biopharmaceutical companies, in partnership with Morning Consult.
“Biopharmaceutical science is advancing faster than ever before, and we need a reimbursement system as innovative as the medicines,” said Stephen J. Ubl, president and CEO, Pharmaceutical Research and Manufacturers of America. “Our members are actively collaborating on new approaches to assess and reward value, and, as an industry, we are going to support policies and tools that help facilitate private-sector leadership in creating value-driven health care.”
In addition to Ubl, the event featured:
- Clifford A. Hudis, M.D., FACP, CEO, American Society for Clinical Oncology
- Tanisha Carino, Ph.D., vice president, U.S. public policy, GlaxoSmithKline
- Samuel Nussbaum, M.D., fellow, USC Schaeffer Center, and former chief medical officer, Anthem, Inc.
- Marc M. Boutin, J.D., CEO, National Health Council
- Patricia J. Goldsmith, CEO, CancerCare
Part of the discussion focused on recognizing how partnerships in value-based contracting will play an increasingly important role in the advancement of value-driven health care. However, panelists agreed the opportunity to more broadly employ such approaches hinges on reforming outdated laws and regulations that are making it more difficult to pay for medicines based on the value they provide to patients and the health care system. Panelists also overwhelmingly agreed tools to measure value need to consider patient preferences, recognizing individuals are going to place different value on their ability to be active or symptom-free over the course of their treatments.
An archive of the event can be found here.